Home LiteratureArticle Details
PMID: 16055611 Published · ppublish English Guideline Journal Article Practice Guideline Review

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Thorax ·Vol. 60 ·No. 10 ·2005-10-00 ·Pages 800-5

British Thoracic Society Standards of Care Committee

Abstract

Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor alpha (anti-TNF-alpha) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

MeSH Terms
Adolescent Adult Aged Algorithms Antitubercular Agents/adverse effects Chemical and Drug Induced Liver Injury/etiology Child Child, Preschool Humans Infant Infant, Newborn Middle Aged Mycobacterium tuberculosis Risk Factors Tuberculosis/drug therapy Tumor Necrosis Factor-alpha/therapeutic use
Chemicals
Antitubercular Agents Tumor Necrosis Factor-alpha
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
British Thoracic Society Standards of Care Committee
References (15)
15 references, click to expand
  1. New drugs for the treatment of rheumatoid arthritis.
    Am J Health Syst Pharm. 2000 Feb 1;57(3):225-34 PMID: 10674776
  2. The treatment of tuberculosis in HIV-infected persons.
    AIDS. 1999 Mar 11;13(4):435-45 PMID: 10197371
  3. Cytokine pathways and joint inflammation in rheumatoid arthritis.
    N Engl J Med. 2001 Mar 22;344(12):907-16 PMID: 11259725
  4. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
    N Engl J Med. 2001 Oct 11;345(15):1098-104 PMID: 11596589
  5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Ann Intern Med. 2002 Oct 15;137(8):640-7 PMID: 12379063
  6. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
    Int J Tuberc Lung Dis. 2002 Nov;6(11):995-1000 PMID: 12475146
  7. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.
    Lancet Infect Dis. 2003 Mar;3(3):148-55 PMID: 12614731
  8. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    Am J Respir Crit Care Med. 2003 Mar 15;167(6):824-7 PMID: 12446275
  9. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.
    Arthritis Rheum. 2004 Feb;50(2):372-9 PMID: 14872478
  10. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.
    Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13 PMID: 15067625
  11. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis.
    Am Rev Respir Dis. 1973 Apr;107(4):523-9 PMID: 4697661
  12. Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group.
    Thorax. 1997 Dec;52(12):1060-7 PMID: 9516900
  13. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.
    Inflamm Bowel Dis. 1998 Nov;4(4):328-9 PMID: 9836088
  14. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    JAMA. 1999 Mar 17;281(11):1014-8 PMID: 10086436
  15. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998.
    Thorax. 2001 Mar;56(3):173-9 PMID: 11182007
Article Info
Journal
Thorax
Abbr.
Thorax
ISSN
0040-6376
DOI
10.1136/thx.2005.046797
Published
2005-10-00
Epub
2005-00-29
Pages
800-5
Language
English
Region
England
NLM ID
0417353
PMCID
PMC1747200
Subset
IM
External Links
PubMed source DOI: 10.1136/thx.2005.046797 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2